Janré Steyn

Janré Steyn

Auto-generated profile, based on publicly available information

Janré Steyn

Department of Science and Innovation - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
JWJennifer Williams
Jennifer Williams
JSJanré Steyn
Janré Steyn
Emilyn Costa ConceicaoEmilyn Costa Conceicao
Emilyn Costa Conceicao
FWFelicia Bernita Wells-Hunter
Felicia Bernita Wells-Hunter
MGMelanie Grobbelaar
Melanie Grobbelaar
JMJohn Z. Metcalfe
John Z. Metcalfe
Next-generation sequencing (NGS) is now recognized as a powerful tool for timely and accurate drug-resistant tuberculosis (DR-TB) diagnosis. Targeted NGS (tNGS) offers a streamlined approach by focusing on specific genes associated with drug resistance, bypassing the need for traditional culture-based methods with turnaround times ranging from weeks to months. The World Health Organization (WHO) has recommended tNGS as a valuable strategy for improving tuberculosis (TB) diagnosis to guide treatment and improve treatment outcomes, particularly in resource-limited settings. Among the WHO-recommended tNGS assays, we have selected a method that provides rapid and comprehensive drug susceptibility testing, lineage determination, and strain typing. While standardized DNA extraction methods are available, they can be time-consuming and labor-intensive. To address this challenge, we optimized a simplified, matrix-based DNA extraction protocol in combination with magnetic bead purification. This method offers a rapid and efficient approach for extracting DNA directly from decontaminated sputum sediments, enabling rapid downstream tNGS analysis. By streamlining the DNA extraction process from sputum sediment, this protocol could facilitate wider adoption of tNGS in routine clinical settings, ultimately contributing to improved patient outcomes and lending to global TB control efforts.

29 August 2025
Verified
Dataset
Closed access
PDF file
MMMorwasehla Modjadji
Morwasehla Modjadji
BMBrendon Coenrad Mann
Brendon Coenrad Mann
JLJohannes Loubser
Johannes Loubser
JWJennifer Williams
Jennifer Williams
JSJanré Steyn
Janré Steyn
RWRobin Mark Warren
Robin Mark Warren
The World Health Organization (WHO) continues to emphasize the urgent need for a rapid, cost-effective, and user-friendly diagnostic method for tuberculosis (TB) and drug-resistant TB (DR-TB). Next-generation sequencing (NGS) technologies, endorsed by the WHO, have significantly improved the detection of DR-TB. Among these, targeted NGS (tNGS) enables focused detection of genetic mutations associated with drug resistance, eliminating the need for traditional culture-based diagnostics. One widely used tNGS assay provides rapid and comprehensive drug susceptibility testing but has been primarily optimized for sequencing platforms with high accuracy. However, the high cost of these sequencing systems has limited accessibility in low- and middle-income countries, particularly across Africa. Portable sequencing technologies present a promising alternative, offering flexibility and reduced infrastructure requirements. In this study, DNA was extracted from rifampicin-resistant TB (RR-TB) isolates, amplified using a tNGS assay, and sequenced on a portable sequencing platform. The same amplification products were also sequenced on a high-accuracy short-read sequencing platform to serve as a reference. Data from the portable sequencer were processed using a bioinformatics pipeline designed for long-read sequencing, while short-read sequencing data were analyzed using an established web-based application. The analysis showed that the long-read sequencing approach successfully identified high-frequency resistance-associated variants detected by short-read sequencing but exhibited limitations in detecting low-frequency variants.

29 August 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
MMMorwasehla Modjadji
Morwasehla Modjadji
BMBrendon Coenrad Mann
Brendon Coenrad Mann
JLJohannes Loubser
Johannes Loubser
JWJennifer Williams
Jennifer Williams
JSJanré Steyn
Janré Steyn
RWRobin Mark Warren
Robin Mark Warren
The World Health Organization (WHO) continues to emphasize the urgent need for a rapid, cost-effective, and user-friendly diagnostic method for tuberculosis (TB) and drug-resistant TB (DR-TB). Next-generation sequencing (NGS) technologies, endorsed by the WHO, have significantly improved the detection of DR-TB. Among these, targeted NGS (tNGS) enables focused detection of genetic mutations associated with drug resistance, eliminating the need for traditional culture-based diagnostics. One widely used tNGS assay provides rapid and comprehensive drug susceptibility testing but has been primarily optimized for sequencing platforms with high accuracy. However, the high cost of these sequencing systems has limited accessibility in low- and middle-income countries, particularly across Africa. Portable sequencing technologies present a promising alternative, offering flexibility and reduced infrastructure requirements. In this study, DNA was extracted from rifampicin-resistant TB (RR-TB) isolates, amplified using a tNGS assay, and sequenced on a portable sequencing platform. The same amplification products were also sequenced on a high-accuracy short-read sequencing platform to serve as a reference. Data from the portable sequencer were processed using a bioinformatics pipeline designed for long-read sequencing, while short-read sequencing data were analyzed using an established web-based application. The analysis showed that the long-read sequencing approach successfully identified high-frequency resistance-associated variants detected by short-read sequencing but exhibited limitations in detecting low-frequency variants.

6 June 2025
Verified
Dataset
Closed access
PDF file
JWJennifer Williams
Jennifer Williams
JSJanré Steyn
Janré Steyn
Emilyn Costa ConceicaoEmilyn Costa Conceicao
Emilyn Costa Conceicao
FWFelicia Bernita Wells-Hunter
Felicia Bernita Wells-Hunter
MGMelanie Grobbelaar
Melanie Grobbelaar
JMJohn Z. Metcalfe
John Z. Metcalfe
Next-generation sequencing (NGS) is now recognized as a powerful tool for timely and accurate drug-resistant tuberculosis (DR-TB) diagnosis. Targeted NGS (tNGS) offers a streamlined approach by focusing on specific genes associated with drug resistance, bypassing the need for traditional culture-based methods with turnaround times ranging from weeks to months. The World Health Organization (WHO) has recommended tNGS as a valuable strategy for improving tuberculosis (TB) diagnosis to guide treatment and improve treatment outcomes, particularly in resource-limited settings. Among the WHO-recommended tNGS assays, we have selected a method that provides rapid and comprehensive drug susceptibility testing, lineage determination, and strain typing. While standardized DNA extraction methods are available, they can be time-consuming and labor-intensive. To address this challenge, we optimized a simplified, matrix-based DNA extraction protocol in combination with magnetic bead purification. This method offers a rapid and efficient approach for extracting DNA directly from decontaminated sputum sediments, enabling rapid downstream tNGS analysis. By streamlining the DNA extraction process from sputum sediment, this protocol could facilitate wider adoption of tNGS in routine clinical settings, ultimately contributing to improved patient outcomes and lending to global TB control efforts.

13 June 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
JLJason D. Limberis
Jason D. Limberis
ANAlina Nalyvayko
Alina Nalyvayko
JSJanré Steyn
Janré Steyn
JWJennifer Williams
Jennifer Williams
MGMelanie Grobbelaar
Melanie Grobbelaar
JMJohn Z. Metcalfe
John Z. Metcalfe
Tuberculosis is a deadly disease, and the emergence of antibiotic drug resistance in the causative agent bacterium, Mycobacterium tuberculosis, worsens treatment outcomes. Precise and rapid drug resistance identification through sequencing technologies is needed to improve tuberculosis patient outcomes through tailored therapeutic regimens. The DNA extraction method is critical for downstream molecular assays and is complicated by the tough cell wall of Mycobacterium, the low bacillary load of many clinical samples, and the complexity of the sputum matrix. There are numerous M. tuberculosis DNA extraction methods reported, but there is currently no gold standard. Furthermore, few of these methods are shown to work consistently, and many are not suitable for low-resource and high-burden tuberculosis settings. Consequently, laboratories frequently introduce their own procedure modifications, resulting in significant method variability. Here, we present a cost-effective, rapid, and standardized protocol for Mycobacterial DNA extraction from both clinical sputum and culture that produces DNA suitable for qPCR, and which should be considered for use in clinical diagnostics laboratories.

13 June 2025
Verified
Dataset
Closed access
PDF file
JLJason D. Limberis
Jason D. Limberis
ANAlina Nalyvayko
Alina Nalyvayko
JSJanré Steyn
Janré Steyn
JWJennifer Williams
Jennifer Williams
MGMelanie Grobbelaar
Melanie Grobbelaar
JMJohn Z. Metcalfe
John Z. Metcalfe
Tuberculosis is a deadly disease, and the emergence of antibiotic drug resistance in the causative agent bacterium, Mycobacterium tuberculosis, worsens treatment outcomes. Precise and rapid drug resistance identification through sequencing technologies is needed to improve tuberculosis patient outcomes through tailored therapeutic regimens. The DNA extraction method is critical for downstream molecular assays and is complicated by the tough cell wall of Mycobacterium, the low bacillary load of many clinical samples, and the complexity of the sputum matrix. There are numerous M. tuberculosis DNA extraction methods reported, but there is currently no gold standard. Furthermore, few of these methods are shown to work consistently, and many are not suitable for low-resource and high-burden tuberculosis settings. Consequently, laboratories frequently introduce their own procedure modifications, resulting in significant method variability. Here, we present a cost-effective, rapid, and standardized protocol for Mycobacterial DNA extraction from both clinical sputum and culture that produces DNA suitable for qPCR, and which should be considered for use in clinical diagnostics laboratories.